<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558713</url>
  </required_header>
  <id_info>
    <org_study_id>1312010-25</org_study_id>
    <nct_id>NCT01558713</nct_id>
  </id_info>
  <brief_title>Epidural Volume Extension and Intrathecal Use of Local Anesthetics in Cesarean Sections</brief_title>
  <official_title>Assessment of Sensory and Motor Block After Intrathecal Administration of Bupivacaine, Ropivacaine and Levo-bupivacaine Combined With Small Doses of Fentanyl, Followed by Administration of Normal Saline Epidurally:a Clinical Trial in Parturients Scheduled for C-section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intrathecal (i.t.) administration of isobaric bupivacaine, ropivacaine and levobupivacaine
      with addition of fentanyl for c-section either combined or not with administration of 10 ml
      of N/S 0,9% epidurally, in order to extent epidural space.Sensory and motor block profile,
      haemodynamics and side effects were assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parturients scheduled for elective caesarean section are randomly allocated to 6 groups: they
      receive double-blindly intrathecal isobaric bupivacaine 10 mg ( Group B), ropivacaine 15mg
      (Group R) , levobupivacaine 10mg (Group L) combined with 10 μg fentanyl and followed by
      epidural administration of 10 ml of N/S 0,9% respectively, and isobaric bupivacaine 10 mg (
      Group BupivacaineF), ropivacaine 15mg (Group RopivacaineF) , and levobupivacaine 10mg (Group
      LevobupivacaineF) combined with 10 μg fentanyl without epidural administration of 10 ml of
      N/S 0,9%. Clinical endpoints are the sensory and motor block profile, haemodynamics (arterial
      pressure, heart rate) and side effects.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dermatomes of Sensory block</measure>
    <time_frame>up to 120 minutes average</time_frame>
    <description>Dermatomes of sensory block(pin prick test) are assessed every minute for the first 30 minutes after the intrathecal administration of local anesthetics and there after every 5 minutes until withdrawal of sensory block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motor block</measure>
    <time_frame>up to 120 minutes average</time_frame>
    <description>Motor block according to the Bromage scale are assessed every minute for the first 30 minutes after the intrathecal administration of local anesthetics and there after every 5 minutes until withdrawal motor block</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial Blood Pressure</measure>
    <time_frame>up to 120 minutes average</time_frame>
    <description>Measurements assesed every minute within the first 30 minutes after the intrathecal administration of local anesthetics and every 5 minutes until withdrawal of sensory and motor block</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Stillborn Caesarean Section</condition>
  <arm_group>
    <arm_group_label>Group BFS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group RFS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group R : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group LFS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group L: LEVO-BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BupivacaineF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group BupivacaineF: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RopivacaineF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group RopivacaineF : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LevobupivacaineF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group LevobupivacaineF: LEVO-BUPIVACAINE 0,5% (2ml) + 10μg FENTANYL(0,2ml) INTRATHECALLY.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine- Fentanyl - Normal Saline</intervention_name>
    <description>Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus</description>
    <arm_group_label>Group BFS</arm_group_label>
    <other_name>Bupivacaine hydrochloride 0.5% ( Marcaine Spinal, 5 mg/ml, AstraZeneca, Missisipi, ON, Canada)</other_name>
    <other_name>Fentanyl, 50μg/ml, Janssen-Cilag, Belgium</other_name>
    <other_name>0,9% Sodium Chloride Inj. BP, B.BRAUN Melsungen AG, German</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine-Fentanyl-Normal Saline</intervention_name>
    <description>Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus</description>
    <arm_group_label>Group RFS</arm_group_label>
    <other_name>Ropivacaine 0.75% :( Naropeine 7.5mg/ml, AstraZeneca)</other_name>
    <other_name>Fentanyl: 50μg/ml, Janssen-Cilag, Belgium</other_name>
    <other_name>0,9% Sodium Chloride Inj. BP, B.Braun Melsungen AG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine- Fentanyl- Normal Saline</intervention_name>
    <description>Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus</description>
    <arm_group_label>Group LFS</arm_group_label>
    <other_name>Chirocaine 5mg/ml, Abbot Laboratories, Greece</other_name>
    <other_name>Fentanyl, 50μg/ml, Janssen-Cilag, Belgium</other_name>
    <other_name>0,9% Sodium Chloride Inj. BP, B.Braun Melsungen AG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine + Fentanyl</intervention_name>
    <description>Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus</description>
    <arm_group_label>BupivacaineF</arm_group_label>
    <other_name>Bupivacaine hydrochloride 0,5% (Marcaine Spinal, 5mg/ml,AstraZeneca,Missisipi, ON, Canada)</other_name>
    <other_name>Fentanyl, 50μg/ml (Janssen-Cilag, Belgium)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine + Fentanyl</intervention_name>
    <description>Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.</description>
    <arm_group_label>RopivacaineF</arm_group_label>
    <other_name>Ropivacaine 0,75% :(Naropeine 7,5mg/ml, AstraZeneca)</other_name>
    <other_name>Fentanyl 50μg/ml, Janssen-Cilag, Belgium.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine + Fentanyl</intervention_name>
    <description>Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus</description>
    <arm_group_label>LevobupivacaineF</arm_group_label>
    <other_name>Chirocaine 5mg/ml, Abbot Laboratories, Greece.</other_name>
    <other_name>Fentanyl 50μg/ml, Janssen-Cilag, Belgium.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective cesarean section

          -  ASA I-II

        Exclusion Criteria:

          -  complicated pregnancy (i.e preeclampsia, eclampsia,arterial hypertension, diabetes
             mellitus)

          -  abnormal fetal heart rate at the time of admission

          -  body mass index &gt; 35 kg/m2

          -  height &lt;150cm and &gt;185 cm

          -  age &lt;18 yrs and &gt;40 yrs

          -  patients with contraindication to spinal anaesthesia( i.e anticoagulants)

          -  ASA &gt;III

          -  intraoperative excessive bleeding

          -  patients with previous psychiatric diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KRITON S FILOS, PROFESSOR</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology and Intensive Care Medicine, University Hospital of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christina G Sklavou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesia and Intensive Care Medicine, University Hospital of Patras</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KRITON S FILOS, PROFESSOR</last_name>
    <phone>+302613603341</phone>
    <phone_ext>+30</phone_ext>
    <email>kritonfilos@yahoo.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CHRISTINA G SKLAVOU, MD</last_name>
    <phone>+302613603346</phone>
    <email>sklavou.christina@yahoo.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anesthesiology and Intensive Care Medicine, University Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KRITON S FILOS, PROFESSOR</last_name>
      <phone>+302613603342</phone>
      <phone_ext>+30</phone_ext>
      <email>kritonfilos@yahoo.gr</email>
    </contact>
    <contact_backup>
      <last_name>Christina G Sklavou, MD</last_name>
      <phone>+306974337046</phone>
      <phone_ext>+30</phone_ext>
      <email>sklavou.christina@yahoo.gr</email>
    </contact_backup>
    <investigator>
      <last_name>Christina G Sklavou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>SKLAVOU CHRISTINA</investigator_full_name>
    <investigator_title>Anesthesiologist- MD</investigator_title>
  </responsible_party>
  <keyword>parturient</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

